Ventus Therapeutics U.S., Inc. announced it raised $70 Million in an initial filing from an offering of $140 Million

Company

Location

About

Ventus Therapeutics is a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunology, inflammation, and neurology disorders. Using its proprietary drug discovery platform, ReSOLVE®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor expected to enter Phase 2 development for Parkinson’s disease and osteoarthritis in obese patients in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S.